Competition record
AstraZeneca
Deep profile · 0 linked library matters
AstraZeneca's core products are Tagrisso in lung cancer, Farxiga in diabetes and heart failure, and the rare-disease franchise it added with Alexion. Hospital pharmacies and national payers, not a consumer aisle, decide whether those brands stay on protocol.
Overview
AstraZeneca is a British-Swedish drug company. Tagrisso is its EGFR lung-cancer pill, Farxiga its SGLT2 pill used in diabetes, heart failure, and kidney disease, and Imfinzi its PD-L1 immunotherapy.
Enhertu, developed with Daiichi Sankyo, competes in HER2 breast cancer, while Lynparza is partnered with Merck. Roche, Merck, Bristol Myers, and Pfizer overlap AstraZeneca in oncology, and the Alexion drugs Ultomiris and Soliris face a much smaller set of complement-inhibitor rivals in rare blood and kidney diseases.
Beyfortus, the infant RSV antibody shared with Sanofi, moves through maternity hospitals and public immunization programs rather than through a retail pharmacy. A tender or a guideline change can swing a season's volume in a way a consumer brand cannot.
Competition footprint
Tagrisso's patent life and diagnostic testing for EGFR mutations gate who can challenge that lung-cancer pill.
Farxiga competes with other SGLT2 drugs for a preferred slot on primary-care formularies.
Ultomiris infusions are scheduled through specialty pharmacies, so a payer policy on rare disease is the access point.
Consumer & business angle
Oncologists follow hospital protocols and companion diagnostics, so a displaced brand loses the whole regimen.
Parents meet Beyfortus as a hospital or clinic dose, with supply set by the season's immunization order.
What to watch
- Guideline and formulary reviews for Tagrisso, Farxiga, and Enhertu as competing regimens publish new data.
- National tenders for Beyfortus and any biosimilar or follow-on that targets Ultomiris or Soliris.
Markets
oncology drugs · cardiovascular drugs · rare disease biologics
Also known as: tagrisso, farxiga, imfinzi, alexion
Conduct themes
Linked cases in the library
No linked matters in the current library yet. The narrative above is still a market-power primer — check primary sources for live disputes.